Baird served as a co-lead manager on this offering
AboutTrius Therapeutics, Inc. (“Trius” or the “Company”) (Nasdaq: TSRX) recently completed a follow-on offering of 7,169,135 shares of its common stock at a price of $4.75 per share, generating gross proceeds of approximately $34.1 million. The Company intends to use the net proceeds from the offering for general corporate purposes, including clinical trial, preclinical and other research and development expenses, capital expenditures, working capital and general and administrative expenses.
Trius is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections. The Company's lead investigational drug, tedizolid phosphate, is a once daily, IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of serious gram-positive infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). Trius has partnered with Bayer HealthCare for the development and commercialization of tedizolid phosphate outside of the U.S., Canada and the European Union. In addition to the Company’s tedizolid phosphate clinical program, Trius has initiated IND enabling studies for its Gyrase-B development candidate with potent activity against Gram-negative bacterial pathogens including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter and Pseudomonas.
For additional information about this transaction, please contact:
- January 2013
- Trius Therapeutics, Inc.
- Target Location
- North America